Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-5150 +/- INO-9012 in Biochemically Relapsed Prostate Cancer
NCT02514213Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-5150 in prostate cancer (PCa) (4 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of INO-5150 alone or with INO-9012 at 72 weeks and Antigen specific immune response at 72 weeks. Started Jul 2015; status: completed.
02
Drugs
INO-5150
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02514213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514213.